Drugs / H1710
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06992713 | Jun 2025 → Sep 2026 expected | neoplasm | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H1710 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06992713 ↗ |